| Title |
Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity?
|
|---|---|
| Published in |
Immunologic Research, November 2014
|
| DOI | 10.1007/s12026-014-8564-6 |
| Pubmed ID | |
| Authors |
Vasco C. Romão, Aurea Lima, Miguel Bernardes, Helena Canhão, João Eurico Fonseca |
| Abstract |
Methotrexate (MTX) is the anchor disease-modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA) treatment. It is used in monotherapy and/or in combination with other synthetic or biological DMARDs, and is known to have the best cost-effectiveness and efficacy/toxicity ratios. However, toxicity is still a concern, with a significant proportion of patients interrupting long-term treatment due to the occurrence of MTX-related adverse drug reactions (ADRs), which are the main cause of drug withdrawal. Despite the extensive accumulated experience in the last three decades, it is still impossible in routine clinical practice to identify patients prone to develop MTX toxicity. While clinical and biological variables, including folate supplementation, partially help to minimize MTX-related ADRs, the advent of pharmacogenomics could provide further insight into risk stratification and help to optimize drug monitoring and long-term retention. In this paper, we aimed to review and summarize current data on low-dose MTX-associated toxicity, its prevention and predictors, keeping in mind practical RA clinical care. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 20% |
| United States | 1 | 20% |
| Mexico | 1 | 20% |
| United Kingdom | 1 | 20% |
| Canada | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 142 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | <1% |
| Unknown | 141 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 21 | 15% |
| Student > Master | 18 | 13% |
| Student > Bachelor | 18 | 13% |
| Researcher | 13 | 9% |
| Other | 11 | 8% |
| Other | 28 | 20% |
| Unknown | 33 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 60 | 42% |
| Agricultural and Biological Sciences | 11 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Biochemistry, Genetics and Molecular Biology | 7 | 5% |
| Immunology and Microbiology | 4 | 3% |
| Other | 14 | 10% |
| Unknown | 39 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 October 2023.
All research outputs
#2,018,069
of 24,584,609 outputs
Outputs from Immunologic Research
#53
of 929 outputs
Outputs of similar age
#23,040
of 263,995 outputs
Outputs of similar age from Immunologic Research
#6
of 32 outputs
Altmetric has tracked 24,584,609 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 929 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,995 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.